-
1
-
-
0034062815
-
American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer
-
American Society of Clinical Oncology Bisphosphonates Expert Panel
-
Hillner BE, Ingle JN, Berenson JR, et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel. J Clin Oncol. 2000;18:1378-1391.
-
(2000)
J Clin Oncol
, vol.18
, pp. 1378-1391
-
-
Hillner, B.E.1
Ingle, J.N.2
Berenson, J.R.3
-
2
-
-
0025329232
-
Overview of cancer-related hypercalcemia: Epidemiology and etiology
-
Muggia FM. Overview of cancer-related hypercalcemia: Epidemiology and etiology. Semin Oncol. 1990;17(Suppl 5):3-9.
-
(1990)
Semin Oncol
, vol.17
, Issue.5 SUPPL.
, pp. 3-9
-
-
Muggia, F.M.1
-
3
-
-
0041152833
-
Metastatic cancer to the bone
-
De Vita VT, Hellman S, Rosenberg SA, eds. Philadelphia, Pa: Lippincott Williams & Wilkins
-
Brown HK, Healy JH. Metastatic cancer to the bone. In: De Vita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2001:2713-2729.
-
(2001)
Cancer: Principles and Practice of Oncology. 6th Ed.
, pp. 2713-2729
-
-
Brown, H.K.1
Healy, J.H.2
-
4
-
-
0025969367
-
Bone metastasis: Pathophysiology and management policy
-
Nielson OS, Munro AJ, Tannock IF. Bone metastasis: Pathophysiology and management policy. J Clin Oncol. 1991;9:509-524.
-
(1991)
J Clin Oncol
, vol.9
, pp. 509-524
-
-
Nielson, O.S.1
Munro, A.J.2
Tannock, I.F.3
-
5
-
-
0036729485
-
American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma
-
Berenson JR, Hillner BE, Kyle RA, et al. American Society of Clinical Oncology clinical practice guidelines: The role of bisphosphonates in multiple myeloma. J Clin Oncol. 2002;20:3719-3736.
-
(2002)
J Clin Oncol
, vol.20
, pp. 3719-3736
-
-
Berenson, J.R.1
Hillner, B.E.2
Kyle, R.A.3
-
6
-
-
0344024906
-
-
East Hanover, NJ: Novartis Pharmaceuticals Corporation
-
Zometa® [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2003.
-
(2003)
Zometa® [Package Insert]
-
-
-
7
-
-
0034986001
-
Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies
-
Green JR. Chemical and biological prerequisites for novel bisphosphonate molecules: Results of comparative preclinical studies. Semin Oncol. 2001;28(Suppl 6):4-10.
-
(2001)
Semin Oncol
, vol.28
, Issue.6 SUPPL.
, pp. 4-10
-
-
Green, J.R.1
-
8
-
-
0037103322
-
Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa)
-
Widler L, Jaeggi KA, Glatt M, et al. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa). J Med Chem. 2002;45:3721-3738.
-
(2002)
J Med Chem
, vol.45
, pp. 3721-3738
-
-
Widler, L.1
Jaeggi, K.A.2
Glatt, M.3
-
9
-
-
0033930168
-
Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298
-
Coxon FP, Helfrich MH, Van't Hof R, et al. Protein geranylgeranylation is required for osteoclast formation, function, and survival: Inhibition by bisphosphonates and GGTI-298. J Bone Miner Res. 2000;15:1467-1476.
-
(2000)
J Bone Miner Res
, vol.15
, pp. 1467-1476
-
-
Coxon, F.P.1
Helfrich, M.H.2
Van't Hof, R.3
-
10
-
-
0035051719
-
Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro
-
Benford HL, McGowan NW, Helfrich MH, et al. Visualization of bisphosphonate-induced caspase-3 activity in apoptotic osteoclasts in vitro. Bone. 2001;28:465-473.
-
(2001)
Bone
, vol.28
, pp. 465-473
-
-
Benford, H.L.1
McGowan, N.W.2
Helfrich, M.H.3
-
11
-
-
0035146537
-
Structure-activity relationships for inhibition of farnesyl disphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates
-
Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl disphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235-242.
-
(2001)
J Pharmacol Exp Ther
, vol.296
, pp. 235-242
-
-
Dunford, J.E.1
Thompson, K.2
Coxon, F.P.3
-
12
-
-
0034214362
-
Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases
-
Boissier S, Ferreras M, Peyruchaud O, et al. Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res. 2000;60:2949-2954.
-
(2000)
Cancer Res
, vol.60
, pp. 2949-2954
-
-
Boissier, S.1
Ferreras, M.2
Peyruchaud, O.3
-
13
-
-
0035866791
-
Bisphosphonate treatment inhibits the growth of prostate cancer cells
-
Lee MV, Fong EM, Singer FR, Guenette RS. Bisphosphonate treatment inhibits the growth of prostate cancer cells. Cancer Res. 2001;61:2602-2608.
-
(2001)
Cancer Res
, vol.61
, pp. 2602-2608
-
-
Lee, M.V.1
Fong, E.M.2
Singer, F.R.3
Guenette, R.S.4
-
14
-
-
0003255113
-
Inhibition of growth of a human prostate cancer cell line with the combination of zoledronic acid and a COX-2 inhibitor
-
Abstract 1827
-
Witters L, Crispino J, Javeed M, et al. Inhibition of growth of a human prostate cancer cell line with the combination of zoledronic acid and a COX-2 inhibitor. Proc Am Soc Clin Oncol. 2002;21:5b. Abstract 1827.
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Witters, L.1
Crispino, J.2
Javeed, M.3
-
15
-
-
0033783227
-
Bisphosphonates induce breast cancer cell death in vitro
-
Fromigue O, Lagneaux L, Body JJ. Bisphosphonates induce breast cancer cell death in vitro. J Bone Miner Res. 2000;15:2211-2221.
-
(2000)
J Bone Miner Res
, vol.15
, pp. 2211-2221
-
-
Fromigue, O.1
Lagneaux, L.2
Body, J.J.3
-
16
-
-
0034980406
-
Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenvironment
-
Mundy GR, Yoneda T, Hiraga T. Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenvironment. Semin Oncol. 2001;28(Suppl 6):35-44.
-
(2001)
Semin Oncol
, vol.28
, Issue.6 SUPPL.
, pp. 35-44
-
-
Mundy, G.R.1
Yoneda, T.2
Hiraga, T.3
-
17
-
-
0012298785
-
Zoledronate induces apoptosis of breast cancer cells in vitro - Evidence for additive and synergistic effects with taxol and tamoxifen
-
Abstract 2619
-
Jagdev SP, Croucher PI, Coleman RE. Zoledronate induces apoptosis of breast cancer cells in vitro - evidence for additive and synergistic effects with taxol and tamoxifen. Proc Am Soc Clin Oncol. 2000;20:664a. Abstract 2619.
-
(2000)
Proc Am Soc Clin Oncol
, vol.20
-
-
Jagdev, S.P.1
Croucher, P.I.2
Coleman, R.E.3
-
18
-
-
0035917560
-
The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel
-
Jagdev SP, Coleman RE, Shipman CM, et al. The bisphosphonate, zoledronic acid, induces apoptosis of breast cancer cells: Evidence for synergy with paclitaxel. Br J Cancer. 2001;84:1126-1134.
-
(2001)
Br J Cancer
, vol.84
, pp. 1126-1134
-
-
Jagdev, S.P.1
Coleman, R.E.2
Shipman, C.M.3
-
19
-
-
0033397214
-
Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment
-
Derenne S, Amiot M, Barillé S, et al. Zoledronate is a potent inhibitor of myeloma cell growth and secretion of IL-6 and MMP-1 by the tumoral environment. J Bone Miner Res. 1999;14:2048-2056.
-
(1999)
J Bone Miner Res
, vol.14
, pp. 2048-2056
-
-
Derenne, S.1
Amiot, M.2
Barillé, S.3
-
20
-
-
0034055664
-
Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines
-
Tassone P, Forciniti S, Galea E, et al. Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines. Leukemia. 2000;14:841-844.
-
(2000)
Leukemia
, vol.14
, pp. 841-844
-
-
Tassone, P.1
Forciniti, S.2
Galea, E.3
-
21
-
-
0037236978
-
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer
-
Corey E, Brown LG, Quinn JE, et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res. 2003;9:295-306.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 295-306
-
-
Corey, E.1
Brown, L.G.2
Quinn, J.E.3
-
22
-
-
0036791075
-
Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model
-
Lee YP, Schwarz EM, Davies M, et al. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model. Cancer Res. 2002;62:5564-5570.
-
(2002)
Cancer Res
, vol.62
, pp. 5564-5570
-
-
Lee, Y.P.1
Schwarz, E.M.2
Davies, M.3
-
23
-
-
6844252283
-
Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events
-
Myeloma Aredia Study Group
-
Berenson JR, Lichtenstein A, Porter L, et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group. J Clin Oncol. 1998;16:593-602.
-
(1998)
J Clin Oncol
, vol.16
, pp. 593-602
-
-
Berenson, J.R.1
Lichtenstein, A.2
Porter, L.3
-
24
-
-
0034937438
-
Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma
-
McCloskey EV, Dunn JA, Kanis JA, et al. Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma. Br J Haematol. 2001;113:1035-1043.
-
(2001)
Br J Haematol
, vol.113
, pp. 1035-1043
-
-
McCloskey, E.V.1
Dunn, J.A.2
Kanis, J.A.3
-
25
-
-
0036721078
-
Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid
-
Wood J, Bonjean K, Ruetz S, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther. 2002;302:1055-1061.
-
(2002)
J Pharmacol Exp Ther
, vol.302
, pp. 1055-1061
-
-
Wood, J.1
Bonjean, K.2
Ruetz, S.3
-
26
-
-
0034326253
-
Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts
-
Reinholz GG, Getz B, Pederson L, et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res. 2000;60:6001-6007.
-
(2000)
Cancer Res
, vol.60
, pp. 6001-6007
-
-
Reinholz, G.G.1
Getz, B.2
Pederson, L.3
-
27
-
-
0042769110
-
Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats
-
Hornby SB, Evans GP, Hornby SL, et al. Long-term zoledronic acid treatment increases bone structure and mechanical strength of long bones of ovariectomized adult rats. Calcif Tissue Int. 2003;72:519-527.
-
(2003)
Calcif Tissue Int
, vol.72
, pp. 519-527
-
-
Hornby, S.B.1
Evans, G.P.2
Hornby, S.L.3
-
28
-
-
0031754524
-
Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys
-
Binkley N, Kimmel D, Brunner J, et al. Zoledronate prevents the development of absolute osteopenia following ovariectomy in adult rhesus monkeys. J Bone Miner Res. 1998;13:1775-1782.
-
(1998)
J Bone Miner Res
, vol.13
, pp. 1775-1782
-
-
Binkley, N.1
Kimmel, D.2
Brunner, J.3
-
29
-
-
0031977199
-
Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras
-
Luckman SP, Hughes DE, Coxon FP, et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581-589.
-
(1998)
J Bone Miner Res
, vol.13
, pp. 581-589
-
-
Luckman, S.P.1
Hughes, D.E.2
Coxon, F.P.3
-
30
-
-
18644373689
-
Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases
-
Chen T, Berenson J, Vescio R, et al. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol. 2002;42:1228-1236.
-
(2002)
J Clin Pharmacol
, vol.42
, pp. 1228-1236
-
-
Chen, T.1
Berenson, J.2
Vescio, R.3
-
32
-
-
0347708657
-
The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal dysfunction
-
Skerjanec A, Berenson J, Hsu C, et al. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal dysfunction. J Clin Pharmacol. 2003;43:154-162.
-
(2003)
J Clin Pharmacol
, vol.43
, pp. 154-162
-
-
Skerjanec, A.1
Berenson, J.2
Hsu, C.3
-
33
-
-
0016916438
-
Prediction of creatinine clearance from serum creatinine
-
Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
-
(1976)
Nephron
, vol.16
, pp. 31-41
-
-
Cockcroft, D.W.1
Gault, M.H.2
-
34
-
-
0032880063
-
A dose-finding study of zoledronate in hypercalcemic cancer patients
-
Body JJ, Lortholary A, Romieu G, et al. A dose-finding study of zoledronate in hypercalcemic cancer patients. J Bone Miner Res. 1999;14:1557-1561.
-
(1999)
J Bone Miner Res
, vol.14
, pp. 1557-1561
-
-
Body, J.J.1
Lortholary, A.2
Romieu, G.3
-
35
-
-
0035863508
-
Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials
-
Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001;19:558-567.
-
(2001)
J Clin Oncol
, vol.19
, pp. 558-567
-
-
Major, P.1
Lortholary, A.2
Hon, J.3
-
36
-
-
0142092856
-
Phase I study of high dose calcitriol (1,25(OH)2 vitamin D3) and zoledronic acid in patients with prostate cancer
-
Abstract 777
-
Solit DB, Smaletz O, DeLaCruz A, et al. Phase I study of high dose calcitriol (1,25(OH)2 vitamin D3) and zoledronic acid in patients with prostate cancer. Proc Am Soc Clin Oncol. 2002;21:195a. Abstract 777.
-
(2002)
Proc Am Soc Clin Oncol
, vol.21
-
-
Solit, D.B.1
Smaletz, O.2
DeLaCruz, A.3
-
37
-
-
0034906503
-
A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases
-
Berenson JR, Vescio RA, Rosen LS, et al. A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastases. Clin Cancer Res. 2001;7:478-485.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 478-485
-
-
Berenson, J.R.1
Vescio, R.A.2
Rosen, L.S.3
-
38
-
-
0035174823
-
A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease
-
Berenson JR, Vescio R, Henick K, et al. A phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease. Cancer. 2001;91:144-154.
-
(2001)
Cancer
, vol.91
, pp. 144-154
-
-
Berenson, J.R.1
Vescio, R.2
Henick, K.3
-
39
-
-
0035312469
-
Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases
-
Berenson JR, Rosen LS, Howell A, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer. 2001;91:1191-1200.
-
(2001)
Cancer
, vol.91
, pp. 1191-1200
-
-
Berenson, J.R.1
Rosen, L.S.2
Howell, A.3
-
40
-
-
0035463593
-
Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial
-
Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: A phase III, double-blind, comparative trial. Cancer J. 2001;7:377-387.
-
(2001)
Cancer J
, vol.7
, pp. 377-387
-
-
Rosen, L.S.1
Gordon, D.2
Kaminski, M.3
-
41
-
-
0037009822
-
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma
-
Saad F, Gleason DM, Murray R, et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst. 2002;94:1458-1468.
-
(2002)
J Natl Cancer Inst
, vol.94
, pp. 1458-1468
-
-
Saad, F.1
Gleason, D.M.2
Murray, R.3
-
42
-
-
10744229392
-
Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases
-
Ibrahim A, Scher N, Williams G, et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res. 2003;9:2394-2399.
-
(2003)
Clin Cancer Res
, vol.9
, pp. 2394-2399
-
-
Ibrahim, A.1
Scher, N.2
Williams, G.3
-
43
-
-
0042914647
-
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group
-
Rosen LS, Gordon G, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin Oncol. 2003;21:3150-3157.
-
(2003)
J Clin Oncol
, vol.21
, pp. 3150-3157
-
-
Rosen, L.S.1
Gordon, G.2
Tchekmedyian, S.3
-
44
-
-
9044219839
-
Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma
-
Myeloma Aredia Study Group
-
Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group. N Engl J Med. 1996;334:488-493.
-
(1996)
N Engl J Med
, vol.334
, pp. 488-493
-
-
Berenson, J.R.1
Lichtenstein, A.2
Porter, L.3
-
45
-
-
0016804136
-
A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival
-
Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842-854.
-
(1975)
Cancer
, vol.36
, pp. 842-854
-
-
Durie, B.G.1
Salmon, S.E.2
-
46
-
-
0027407786
-
The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure
-
Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
-
(1993)
J Clin Oncol
, vol.11
, pp. 570-579
-
-
Cella, D.F.1
Tulsky, D.S.2
Gray, G.3
-
47
-
-
0025688231
-
EuroQol - A new facility for the measurement of health-related quality of life
-
The EuroQol Group
-
EuroQol - a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16:199-208.
-
(1990)
Health Policy
, vol.16
, pp. 199-208
-
-
-
48
-
-
0036899876
-
Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain
-
Walker K, Medhurst SJ, Kidd BL, et al. Disease modifying and anti-nociceptive effects of the bisphosphonate, zoledronic acid in a model of bone cancer pain. Pain. 2002;100:219-229.
-
(2002)
Pain
, vol.100
, pp. 219-229
-
-
Walker, K.1
Medhurst, S.J.2
Kidd, B.L.3
-
49
-
-
0037186926
-
Intravenous zoledronic acid in postmenopausal women with low bone mineral density
-
Reid IR, Borwn JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661.
-
(2002)
N Engl J Med
, vol.346
, pp. 653-661
-
-
Reid, I.R.1
Borwn, J.P.2
Burckhardt, P.3
-
50
-
-
0036606093
-
Diagnosis of osteoporosis and assessment of fracture risk
-
Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 2002;359:1929-1936.
-
(2002)
Lancet
, vol.359
, pp. 1929-1936
-
-
Kanis, J.A.1
-
51
-
-
0038075478
-
Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer
-
Smith MR, Eastham J, Gleason DM, et al. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. J Urol. 2003;169;2008-2012.
-
(2003)
J Urol
, vol.169
, pp. 2008-2012
-
-
Smith, M.R.1
Eastham, J.2
Gleason, D.M.3
-
52
-
-
10744233248
-
Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation
-
Haas M, Leko-Mohr Z, Roschger P, et al. Zoledronic acid to prevent bone loss in the first 6 months after renal transplantation. Kidney Int. 2003;63:1130-1136.
-
(2003)
Kidney Int
, vol.63
, pp. 1130-1136
-
-
Haas, M.1
Leko-Mohr, Z.2
Roschger, P.3
-
53
-
-
0038657557
-
Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis
-
Matsuo A, Shuto T, Hirata G, et al. Antiinflammatory and chondroprotective effects of the aminobisphosphonate incadronate (YM175) in adjuvant induced arthritis. J Rheumatol. 2003;30:1280-1290.
-
(2003)
J Rheumatol
, vol.30
, pp. 1280-1290
-
-
Matsuo, A.1
Shuto, T.2
Hirata, G.3
-
54
-
-
0036187721
-
The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage
-
Muehleman C, Green J, Williams JM, et al. The effect of bone remodeling inhibition by zoledronic acid in an animal model of cartilage matrix damage. Osteoarthritis Cartilage. 2002;10:226-233.
-
(2002)
Osteoarthritis Cartilage
, vol.10
, pp. 226-233
-
-
Muehleman, C.1
Green, J.2
Williams, J.M.3
-
55
-
-
0035049894
-
The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone
-
Garnero P, Christgau S, Delmas PD. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget's disease of bone. Bone. 2001;28:461-464.
-
(2001)
Bone
, vol.28
, pp. 461-464
-
-
Garnero, P.1
Christgau, S.2
Delmas, P.D.3
-
56
-
-
0031886744
-
Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease
-
Garnero P, Gineyts E, Schaffer AV, et al. Measurement of urinary excretion of nonisomerized and beta-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget's disease. Arthritis Rheum. 1998;41:354-360.
-
(1998)
Arthritis Rheum
, vol.41
, pp. 354-360
-
-
Garnero, P.1
Gineyts, E.2
Schaffer, A.V.3
-
57
-
-
0030896159
-
Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone
-
Arden-Cordone M, Siris ES, Lyles KW et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget's disease of bone. Calcif Tissue Int. 1997;60:415-418.
-
(1997)
Calcif Tissue Int
, vol.60
, pp. 415-418
-
-
Arden-Cordone, M.1
Siris, E.S.2
Lyles, K.W.3
-
58
-
-
18844467280
-
Single infusion of zoledronate in Paget's disease of bone: A placebo-controlled, dose-ranging study
-
Buckler H, Fraser W, Hosking D, et al. Single infusion of zoledronate in Paget's disease of bone: A placebo-controlled, dose-ranging study. Bone. 1999;24(Suppl 5):81S-85S.
-
(1999)
Bone
, vol.24
, Issue.5 SUPPL.
-
-
Buckler, H.1
Fraser, W.2
Hosking, D.3
-
59
-
-
0035879143
-
Safety and efficacy of bisphosphonates beyond 24 months in cancer patients
-
Ali SM, Esteva FJ, Hortobagyi G, et al. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol. 2001;19:3434-3437.
-
(2001)
J Clin Oncol
, vol.19
, pp. 3434-3437
-
-
Ali, S.M.1
Esteva, F.J.2
Hortobagyi, G.3
-
60
-
-
0034810866
-
A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease
-
DesHarnais Castel L, Bajwa K, Markle JP, et al. A microcosting analysis of zoledronic acid and pamidronate therapy in patients with metastatic bone disease. Support Care Cancer. 2001;9:545-551.
-
(2001)
Support Care Cancer
, vol.9
, pp. 545-551
-
-
DesHarnais Castel, L.1
Bajwa, K.2
Markle, J.P.3
-
61
-
-
0034660662
-
Bisphosphonates and the prevention of metastasis: First evidences from preclinical and clinical studies
-
Diel IJ, Solomayer EF, Bastert G. Bisphosphonates and the prevention of metastasis: First evidences from preclinical and clinical studies. Cancer. 2000;88(Suppl 12):3080-3088.
-
(2000)
Cancer
, vol.88
, Issue.12 SUPPL.
, pp. 3080-3088
-
-
Diel, I.J.1
Solomayer, E.F.2
Bastert, G.3
-
62
-
-
0034990442
-
Unmet needs in metastatic bone disease and its complications: Is progress possible?
-
Hortobagyi GN. Unmet needs in metastatic bone disease and its complications: Is progress possible? Semin Oncol. 2001;28(Suppl 6):1-3.
-
(2001)
Semin Oncol
, vol.28
, Issue.6 SUPPL.
, pp. 1-3
-
-
Hortobagyi, G.N.1
|